Orthocell Ltd’s Post

Attention #Medtech professionals! Are you interested in hemocompatibility, medical devices, and extracorporeal systems? Then, this exclusive editorial article is for you! It features experts Dr. Andy Herbert, CTO and Co-founder, and Dr. Elizabeth Blackburn, Principal Scientist at Invizius. Providing in-depth insights into the significance of assessing complement activation in dialysis. Don't miss out on this opportunity to enrich your knowledge and contribute to advancing healthcare solutions. Discover how Invizius is assessing complement activation and tackling its challenges. Click the link to download your copy and join the conversation on the relevance of hemocompatibility in extracorporeal systems. https://hubs.ly/Q02vv8PD0 Complement assessment could make a difference! #Hemocompatibility #ExtracorporealSystems #MedicalDevices #Dialysis #HealthcareInnovation #Biocompatibility #SvarLifeScience #ExpertPartner #AnswersinLifeScience #MedTech

This patent, the most recent, extends the reach and control of a new type of diagnostics and therapeutics. "New" is misleading as the patent draws on the importance of tissue energy in relation to disease and healing, already known for millennia beginning with acupuncture and chakras, as images or Aura of bodily health and a portal to healing. I call this H.E.A.L.T.H. or Harmonic Energy Activated Live Tissue Healing. In endometriosis identifying disease causing frequencies allows accurate detection of disease and identifies energy pathways to healing. This technology is already known to modern medicine when knee osteoarthritis is reversed and cartilage regrown with the proper energy input of 7.4 cycles per minute, eliminating need for knee replacement in a double blinded 1980's study from Johns Hopkins. How does it work? The knee bends, energy is emitted, which signals the body to initiate intrinsic healing. This is why sports injuries are no longer handled by immobilization and ice, but rather rapid return to motion, shortening healing from weeks to mere days. Using HEALTH methods there will be a day when you rest in a bed that will sense the energy fingerprint of disease and fix it as you sleep. Stay tuned...more to come...

"Thrilled to share a significant milestone in my journey: my patent for a reusable bone marrow biopsy device has been officially granted! 🌟 This innovation aims to streamline procedures, reduce waste, environment friendly and ultimately enhance patient care in the realm of healthcare. Grateful for the support of my team and mentors #Dasari Yogeshwar, #Prof Ramjee Repaka, #Ashish Sahani throughout this process. Excited for the impact ahead! Also a special thanks to #VIJAY KUMAR SHARMA for thorough discussion and suggestions. #HealthcareInnovation #PatentGranted #BiomedicalEngineering"

#ad Gain expert insights in this panel discussion in which experts review clinical trial outcomes of the #TENEO #excimer #laser for #myopia and myopic #astigmatism. Watch here: https://bit.ly/4hTeb66 For safety info, visit: https://bit.ly/40YnvQ0

📺 STOCKHEAD INTERVIEW This week Orthocell Ltd announced the appointment of two new US-based executives as the Company prepares to enter the US market with its nerve repair product, Remplir™. Orthocell Chairman John Van Der Wielen spoke with Stockhead to share insights into why Remplir represents a compelling investment opportunity. Here's an excerpt: "The difference between Orthocell is you've got a product that's already been used in human bodies. There's over $35 million of cash on the balance sheet, and it's already in revenue with existing regulatory approval. It has crossed that threshold between this amazing concept and something that's actually generating revenue... it's a very low risk biotech compared to the majority of other smaller cap stocks. People are realising this is right on the threshold of coming into profit and significant growth." It's worth a look 👉 https://lnkd.in/giyF7DWT $OCC #Orthocell #nerverepair #medicaldevice #healthcare #medtech #innovation #growth #invest

Setpoint Medical is revolutionizing autoimmune disease treatment with cutting-edge implants for conditions like rheumatoid arthritis, multiple sclerosis, and Crohn's disease, among others. To navigate stringent regulatory requirements, complex manufacturing processes, and the need for precise quality control, the company has relied on Kingstec’s engineering and manufacturing expertise. "Our ability to expediently create a quality manufacturing process is where we're winning...I think a lot of that, honestly, is because of the relationship we have with Kingstec," said John Long, Vice President of Operations at Setpoint Medical. Read the case study to learn more about the impact this collaboration is having on the future of autoimmune disease treatment: https://bit.ly/493CRmW #kingstec #kingstectechnologies #medicaldevice #manufacturing #healthcare

We have just published the latest edition of MedDevNews, our quarterly review of capital markets activity and trends in the medical device sector. Q3 2024 saw improved M&A and IPO activity, as well as a thriving organ transplant market driven by rising demand and advanced preservation technologies. England also attended the Women's Health Innovation Series summit in September and has launched a new Women’s Health sector breakout for market performance analyses. This edition also offers insights on the upcoming election and its potential impacts on medical device markets. England also announced that it served as the exclusive financial advisor to Collagen Solutions, a leader in medical-grade collagen and tissue-based biomaterials, in its sale to RTI Surgical®, a leading tissue engineering CDMO. Read the full Q3 newsletter here: https://lnkd.in/gEwtCsmR #femtech #IPOmarket #markets #medicaldevices #mergersandacquisitions #organtransplant #womenshealth

This one’s a big edition for you medtechies out there. We’re seeing the transaction market turnaround. Also a few special items in here about the transplant market, women’s health (which we’ve started coverage on), election impact considerations, care-based AI and our biomaterials deal.

ENDOSURE, INC. is delighted to announce we have been assigned a newly granted patent for the ENDOSURE TEST! This patent covers the TRICORDER-3L System and innovative AI method of generating and collecting data to read gastrointestinal myoelectrical activity (GIMA). Receiving this patent further affirms ENDOSURE, INC.’s ongoing commitment to advancing early detection and diagnosis of endometriosis with the ENDOSURE TEST -- the only non-invasive, 30-minute, 99+% accurate diagnostic technology that can diagnose the presence of endometriosis regardless of the disease stage (I, II, III, or IV). This milestone brings us one step closer to help the minimum 10% women around the world who are afflicted with this terrible disease, to receive an accurate diagnosis sooner, restoring hope and improving their quality of life. Please join us in celebrating this significant achievement as we continue our efforts to make the ENDOSURE TEST available to women and clinicians around the world. #Endometriosis #WomensHealth #Femtech #Medtech

Surgical staples: Current state-of-the-art and future prospective https://lnkd.in/gd2U_89x Thus, in this literature review, we try to give a comprehensive glimpse of the development and current state-of-the-art surgical staples in consideration with research from a commercial point of view. On a special note, this review also describes a very brief outline of the regulatory aspects and some common internationally acceptable ‘de jure standards for the development of commercially viable surgical staples. #Heterogeneity #innovation #research